Last reviewed · How we verify

MAT2203 — Competitive Intelligence Brief

MAT2203 (MAT2203) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal agent (lipid nanoparticle formulation). Area: Infectious Disease.

phase 3 Antifungal agent (lipid nanoparticle formulation) Fungal cell membrane ergosterol Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

MAT2203 (MAT2203) — Matinas BioPharma Nanotechnologies, Inc.. MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MAT2203 TARGET MAT2203 Matinas BioPharma Nanotechnologies, Inc. phase 3 Antifungal agent (lipid nanoparticle formulation) Fungal cell membrane ergosterol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal agent (lipid nanoparticle formulation) class)

  1. Matinas BioPharma Nanotechnologies, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MAT2203 — Competitive Intelligence Brief. https://druglandscape.com/ci/mat2203. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: